Oral Amylin Drug Shows 3.3% Weight Loss in Single Dose; GLP-1 Hits 16.2% at 72 Weeks
GPCR has more than doubled off its 52-week low of $19.5 on light trading volume (0.4× avg).
Summary
Structure Therapeutics reported positive clinical data for both lead obesity programs. ACCG-2671, an oral amylin agonist, showed a ~6-day half-life, no serious adverse events, and 3.3% body weight loss after a single dose in a Phase 1/2a SAD trial. Aleniglipron, its oral GLP-1, achieved up to 16.2% weight loss at 72 weeks in the ACCESS OLE with fewer than 5% discontinuations due to adverse events. The company also initiated the MAD portion of the ACCG-2671 trial and expects topline data in 1H 2027. These results strengthen the case for oral small molecules in obesity, a market dominated by injectables. The stock is likely to react positively as this is the first clinical validation of the amylin program and reinforces aleniglipron's competitive profile ahead of Phase 3 data in 2H 2028.
At the time of this announcement, GPCR was trading at $47.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $19.50 to $94.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.